Business
-
ReCode Therapeutics has raised $80 million in Series B financing that it will use in large part to fund clinical development of inhaled therapies for cystic fibrosis and primary ciliary dyskinesia (PCD), the company said.… Read more . . .
-
Shandong Luoxin Pharmaceutical will pay $2 million up front plus milestone payments of up to $20 million to acquire exclusive rights to develop, manufacture, and commercialize Marninomed’s Budesolv budesonide nasal spray in China, the company has… Read more . . .
-
Argentinian pharma company Biosidus and Crystec have announced a new deal for development of dry powder formulations of Biosidus drugs for inhaled and/or nasal delivery using Crystec’s mSAS supercritical fluid particle engineering technology. The first… Read more . . .
-
Bayer HealthCare and Meda Pharmaceuticals have filed a patent infringement suit against Apotex after Apotex submitted an ANDA for a generic version of Astepro Allergy azelastine hydrochloride nasal spray, 0.15%. The FDA approved Bayer’s NDA… Read more . . .
-
According to Liquidia Corporation, an inter partes review by the US Patent Trial and Appeal Board (PTAB) regarding US Patent No. 9,604,901, which is listed in the Orange Book as one of 7 patents covering United Therapeutics’… Read more . . .
-
Glenmark Pharmaceuticals has announced the launch of its version of Spiriva Handihaler tiotropium bromide DPI in Spain, where it will be known as Tavulus. In August 2018, Glenmark announced that it had acquired the rights… Read more . . .
-
Oncotelic Therapeutics (formerly Mateon Therapeutics) announced that it has licensed an intranasal apomorphine formulation from Autotelic, Inc, a newly formed company owned largely by Oncotelic Chairman and CEO, Vuong Trieu. Oncotelic says that it plans… Read more . . .
-
Glenmark Pharmaceuticals said that its Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of seasonal and perennial allergic rhinitis has received final marketing approval in 13 countries in Europe and the UK. Earlier this… Read more . . .
-
The COPD Foundation has partnered with Renovion on development of Renovion’s ARINA-1 nebulized glutathione / bicarbonate / ascorbic acid for the treatment of COPD and non-cystic fibrosis bronchiectasis, the foundation said. ARINA-1, which is delivered… Read more . . .
-
GlaxoSmithKline has announced an initiative to evaluate a new lower global warming potential propellant for its metered dose inhalers as part of an effort to reach net zero carbon emissions. According to GSK, its Ventolin… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK


